X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Omjjara (momelotinib) is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. It is indicated for the treatment of splenomegaly (enlarged spleen) or symptoms in adult myelofibrosis patients with moderate to severe anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Hematology Product Name: Omjjara
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
GS-0387 (momelotinib) has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1). It is being evaluated for the treatment of myelofibrosis patients with anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Ojjaara (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is approved for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: Ojjaara
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Details:
GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1 and JAK2 and activin A receptor type I (ACVR1).
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
GS-0387 (momelotinib) is a potential new medicine with a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, and JAK2 and activin A receptor, type I (ACVR1).
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022
Details:
Momelotinib (GS-0387), has a differentiated mode of action with inhibitory ability along three key signalling pathways: activin A receptor, type I (ACVR1)/activin receptor-like kinase-2 (ALK2), Janus kinase (JAK) 1, and JAK2.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition July 01, 2022
Details:
GS-0387 (momelotinib) is a potent, selective and orally bioavailable ACVR1 / ALK2, JAK1, JAK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
GS-0387 (Momelotinib) is potent, selective and orally bioavailable ACVR1 / ALK2, JAK1, JAK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
MOMENTUM data selected for an oral presentation at EHA demonstrated that GS-0387 (momelotinib) achieved statistically significant and clinically important efficacy across all prespecified primary and key secondary endpoints.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
The proposed acquisition aligns with GSK’s strategy of building a strong portfolio of new specialty medicines, vaccines and momelotinib to make GSK’s commercial and medical in haematology and rare forms of cancer.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition April 13, 2022
Details:
Sierra Oncology intends to use the net proceeds of the offering to prepare for potential commercialization of momelotinib, clinical development of its other product candidates, research, clinical and process development and manufacturing of its product candidates.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $135.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 31, 2022
Details:
Momelotinib is a potent, selective and orally bioavailable JAK1, JAK2 and ACVR1 / ALK2 inhibitor under investigation for the treatment of myelofibrosis in symptomatic, anemic patients previously treated with an approved JAK inhibitor.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2022
Details:
Momelotinib is an orally bioavailable JAK1, JAK2 and ACVR1 / ALK2 inhibitor, currently under investigation in MOMENTUM clinical trial Phase 3 study for symptomatic and anemic myelofibrosis patients.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
These funds are in addition to the $90.7 million in cash and cash equivalents on hand at the close of the second quarter of 2021, further bolstering the company’s cash balance as it prepares for momelotinib commercialization.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $158.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 09, 2021
Details:
AZD5153 is a selective BRD4 inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, resulting in improved potency.
Lead Product(s): Momelotinib,AZD5153
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 05, 2021
Details:
Data highlights improved transfusion independence of momelotinib irrespective of baseline degree of anemia, platelet count or transfusion status. Efficacy data examining the association between transfusion independence and overall survival for momelotinib.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Robust overall survival and sustained efficacy outcomes during long term exposure to Momelotinib in JAK inhibitor Naïve and previously JAK Inhibitor treated intermediate/high risk myelofibrosis patients.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Mr. Kevin Norrett will support Sierra's MOMENTUM Phase 3 trial and delivering a high-quality outcome that may enable momelotinib's global registration.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib.
Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.
Lead Product(s): SRA737,Momelotinib,Aphidicolin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
